The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid caseload to ensure smooth and fast delivery of the medicine, the centre said in a statement. The statement also mentioned the production capacity is being ramped up from current level of 38 lakh vials per month to 74 lakh vials per month, and 20 additional manufacturing sites have been approved. ‘Export of remdesivir has also been prohibited in order to shore up domestic supplies’ it said.
The Health Ministry and the Department of Pharmaceuticals have made an interim allocation of remdesivir for 19 states and UTs up to April 30. "This allocation pertains to 14 states to which medical oxygen is allocated and five other states where the high volume of supplies are being observed," the centre said.